See what’s changing first. Know which accounts matter next.
Fundz catches funding rounds before they’re announced, and acquisitions, new executives, hiring shifts and contract wins as they happen. It weighs them against your ideal customer profile and delivers a ranked shortlist every morning, with the evidence, the reason to reach out and the decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
AvenCell Therapeutics secures $47M from Ligand Pharmaceuticals for Series C financing and CAR-T drug development, with funding tied to clinical milestones.
Amount Raised
$47 Million
Round Type
Series C
CambridgeBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
AvenCell Therapeutics, a clinical-stage CAR-T therapy developer, announced a $47 million financing agreement with Ligand Pharmaceuticals on September 24, 2026. The deal comprises $6 million committed to AvenCell's Series C financing round and $41 million for drug development programs. The larger commitment is structured in tranches, with the first payment due at closing and three additional tranches contingent on predetermined clinical milestones and financing conditions. In return, Ligand will receive royalty interests ranging from mid-single-digit to low-double-digit royalties on AvenCell's products if they succeed commercially.
Fundz sees it the moment AvenCell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
AvenCell Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.